FDA shoves Bay­er’s lym­phoma drug co­pan­lis­ib in­to the spot­light with its promise of a speedy re­view

Bay­er is get­ting VIP treat­ment at the FDA for its mid-stage lym­phoma drug co­pan­lis­ib. Reg­u­la­tors agreed to give the drug a pri­or­i­ty re­view

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.